Content area
Full text
The AllTrials campaign, striving to achieve full disclosure of all results in clinical trials, recently conducted an audit of the transparency policies of pharmaceutical companies, finding them open enough on the surface — but beset with devils in the details.
Researchers scrutinized the trial registration and reporting policies of major pharmaceutical companies worldwide in what is apparently the first such attempt to systematically examine drug company policies on trial transparency. It is something of an understatement to say the results were mixed, with gains in transparency in one area offset by impenetrable policies in another.
They found that most large companies have some manner of publicly stated policy about registering and reporting results from current trials. However, only around half of the company policies examined revealed results from...